Combination of CBD and CBDV for regulation of CXCR4 expression on immune cells

Researcher:

The Technology

CXCR4 is a membranal chemokine receptor expressed at different levels by all immune cells, and plays a homeostatic role in homing and retention of immune cells. In addition, this receptor is one of the co-receptors for HIV, is expressed by multiple cancers including breast, prostate, lung, colon and multiple myeloma. CXCR4 was found to play a significant role in tumour development of both solid and blood cancers. CXCR4 is involved in vrious inflammatory condition, thus, regulation of this molecule can result in inflammation reduction in chronic condition such as IBD or autoimmune diseases (e.g. multiple sclerosis). In addition, CXCR4 is associated with poor prognosis in clinical studies of multiple cancer types. Importantly, there is evidence that inhibition of CXCR4 prevents proliferation and metastasis in various cancer. Due to the role of CXCR4 in HIV and in cancer, multiple CXCR4 antagonists are being evaluated. Nevertheless, ccurrently there is only one approved CXCR4 antagonist, Mozobil (also known as Plerixafor and AMD3100). Mozobil has several side effects such as bleeding gums, coughing up blood, f blood accumulation under the skin,breathing or swallowing difficulties etc. . The research lab identified a synergistic effect between CBD and CBDV in reducing CXCR4 expression on a verity of immune cells, as well as a new function for two known molecules, Cannabidiol (CBD) and Cannabidivarin (CBDV) that are presumed to be safe for human use. Thus, combination of CBD and CBDV can be used for regulation of CXCR4 expression on immune cells, and may serve a novel therapy for several inflammation, autoimmune and cancer diseases.